JP2010511382A - 癌関連タンパク質キナーゼ - Google Patents

癌関連タンパク質キナーゼ Download PDF

Info

Publication number
JP2010511382A
JP2010511382A JP2009539218A JP2009539218A JP2010511382A JP 2010511382 A JP2010511382 A JP 2010511382A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2010511382 A JP2010511382 A JP 2010511382A
Authority
JP
Japan
Prior art keywords
ack1
epha2
tyk2
lmtk2
ron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009539218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511382A5 (enExample
Inventor
アクセル ウーリッヒ、
ジェンス リューエ、
ステファン ハート、
シルビア ストレイト、
チー ホン ウォン、
ブーン ティン チュア、
ハン キアット ホー、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2010511382A publication Critical patent/JP2010511382A/ja
Publication of JP2010511382A5 publication Critical patent/JP2010511382A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009539218A 2006-12-01 2007-12-03 癌関連タンパク質キナーゼ Pending JP2010511382A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86817306P 2006-12-01 2006-12-01
PCT/SG2007/000412 WO2008066498A1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Publications (2)

Publication Number Publication Date
JP2010511382A true JP2010511382A (ja) 2010-04-15
JP2010511382A5 JP2010511382A5 (enExample) 2011-01-27

Family

ID=39468190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539218A Pending JP2010511382A (ja) 2006-12-01 2007-12-03 癌関連タンパク質キナーゼ

Country Status (5)

Country Link
US (1) US20110008347A1 (enExample)
EP (1) EP2094850B1 (enExample)
JP (1) JP2010511382A (enExample)
SG (1) SG177225A1 (enExample)
WO (1) WO2008066498A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500638A (ja) * 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2017531433A (ja) * 2014-10-09 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 上皮細胞増殖因子受容体キナーゼドメインにおける変異

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
NZ577759A (en) * 2007-01-11 2012-07-27 Genentech Inc Genetic variations of tyrosine kinase 2 resulting in an activated catalytic domain are associated with colon and stomach cancer
LT2199390T (lt) 2007-08-30 2017-03-10 Daiichi Sankyo Company, Limited Anti-epha2 antikūnas
US8540998B2 (en) 2007-12-24 2013-09-24 Oxford Biotherapeutics Ltd. Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
EP2252373B1 (en) * 2008-02-05 2012-06-13 Urifer Ltd Novel fer -like protein, pharmaceutical compositions containing it and method for its use
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2169071A1 (en) * 2008-09-29 2010-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rodent cancer model for human FGFR4 Arg388 polymorphism
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
CA2741087A1 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
NZ593207A (en) 2008-11-12 2012-10-26 Tengion Inc Isolated renal cells and uses thereof
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
DK3248610T5 (da) 2009-05-05 2024-10-07 Amgen Inc Fgf21-mutanter og anvendelser deraf
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US10077442B2 (en) 2010-05-12 2018-09-18 Inregen Bioactive renal cells
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
AU2011336650B2 (en) 2010-12-01 2016-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
US10293035B2 (en) 2014-03-28 2019-05-21 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
CN107406492B (zh) * 2014-09-03 2021-12-24 井标记生物 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途
AU2016270321B2 (en) * 2015-05-29 2020-09-10 Ignyta, Inc. Compositions and methods for treating patients with RTK mutant cells
MX382526B (es) 2015-10-23 2025-03-13 Array Biopharma Inc Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
AU2017210327A1 (en) 2016-01-20 2018-08-09 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
CN106480205A (zh) * 2016-11-11 2017-03-08 北京吉因加科技有限公司 用于同时检测多种突变类型的序列组合和探针
IL271759B2 (en) 2017-07-19 2024-01-01 Ignyta Inc Pharmaceutical preparations that include anthraxtinib
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
JP7041265B2 (ja) * 2017-11-29 2022-03-23 ソウル大学校産学協力団 抗－ｒｏｓ１抗体およびその用途
WO2019133752A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology A method for predicting drug efficacy
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
WO2020179844A1 (ja) * 2019-03-04 2020-09-10 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2022147246A1 (en) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
WO2022182972A1 (en) 2021-02-26 2022-09-01 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
WO2024006883A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
AU2023300362A1 (en) 2022-06-29 2025-01-09 Tyra Biosciences, Inc. Indazole compounds
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
TW202535368A (zh) 2023-12-15 2025-09-16 美商泰拉生物科學公司 吲唑化合物
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
CA2425643A1 (en) * 2000-10-11 2002-04-18 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2003225535A1 (en) * 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
JP2006174701A (ja) * 2003-02-24 2006-07-06 Research Association For Biotechnology 新規タンパク質およびそれをコードするｄｎａ
JP2005198640A (ja) * 2003-11-25 2005-07-28 Biomarker Science:Kk 遺伝子発現方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012059376; Ｉｎｔ．Ｊ．Ｃａｎｃｅｒ．，２００４　Ａｕｇ　２０，１１１（２），ｐ．２１３-７ *
JPN6012059377; Ｂｒ．Ｊ．Ｃａｎｃｅｒ．，２００６　Ｊｕｎ　１９，９４（１２），ｐ．１８７９-８６ *
JPN6012059379; Ｊ．Ｃｌｉｎ．Ｏｎｃｏｌ．，２００６　Ａｕｇ　１０，２４（２３），ｐ．３７４７-５５ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500638A (ja) * 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2017531433A (ja) * 2014-10-09 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 上皮細胞増殖因子受容体キナーゼドメインにおける変異

Also Published As

Publication number Publication date
WO2008066498A1 (en) 2008-06-05
EP2094850B1 (en) 2013-06-12
EP2094850A1 (en) 2009-09-02
SG177225A1 (en) 2012-01-30
EP2094850A4 (en) 2010-08-04
US20110008347A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
JP2010511382A (ja) 癌関連タンパク質キナーゼ
Bourguignon et al. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration
US9364477B2 (en) Mutant ROS expression in human cancer
JP6575950B2 (ja) Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
KR101862719B1 (ko) 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도
US20100081153A1 (en) Cancer associated protein kinases and their uses
US20170107579A1 (en) E1 enzyme mutants and uses thereof
JP2004504009A (ja) 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素
WO2013024144A1 (en) Markers for susceptibility to an inhibitor of an src-family kinase
CN101732717A (zh) 用于诊断和作为癌症治疗靶标的ttk
Uchida et al. Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation
US20060141529A1 (en) Compositions, kits and assays containing reagents directed to cortactin and an ARG/ABL protein kinase
CA2697887A1 (en) Modulating and/or detecting activation induced deaminase and methods of use thereof
Shillingford Insights into the Allosteric Regulation and Exploitation of the MAPK Phosphatases as Therapeutic Targets
WO2012075318A2 (en) Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
Montecchini TERAPIA DI PRECISIONE PER LA LEUCEMIA LINFOBLASTICA ACUTA PEDIATRICA BCR-ABL-LIKE: SVILUPPO DI UN SISTEMA IN VITRO PER LA DIAGNOSI E IL MONITORAGGIO CLINICO
US20040048310A1 (en) Novel human protein kinases and protein kinase-like enzymes
Chen et al. Palmitoylation-dependent activation of NADK promotes NADP+ synthesis and tumorigenesis
Mutic Effect of MAPK inhibition on cell cycle regulation of thymidine kinase 1 and [18F]-FLT PET
Lindholm Bachelor of Science
HK1210482B (en) Mutant ros expression in human liver cancer
AU2007237228A1 (en) Cancer associated protein kinases and their uses
HK1165007B (en) Mutant ros expression in human liver cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702